Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 75

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 75
---
 availability of our CER-T cells
for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of
marketing applications for our CER-T cell product candidates. Significant non-compliance could also result in the imposition of sanctions,
including warning or untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals
for our CER-T cell product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products,
operating restrictions and criminal prosecutions, any of which could damage our reputation and our business.

<div align='center'>37</div>

Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

If the FDA, EMA or any other
comparable regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory
requirements. These requirements include submissions of safety and other post-marketing information and reports, registration requirements,
applicable product tracking and tracing requirements and continued compliance with cGMPs, including cGTPs, and GCP, for any clinical
trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with any future potential manufacturing facilities we may own, third-party manufacturers or manufacturing processes,
or failure to comply with regulatory requirements, may result in, among other things:

| ● | restrictions on the marketing                                                                             
 or manufacturing of the product, withdrawal of the product from the market, or voluntary product recalls; |

| ● | fines, untitled or warning           
 letters or holds on clinical trials; |

| ● | refusal by the FDA, the                                                                                                           
 EMA or any other comparable regulatory authority to approve pending applications or supplements to approved applications filed by 
 us, or suspension or revocation of product approvals;                                                                             |

| ● | product seizure or detention,                              
 or refusal to permit the import or export of products; and |

| ● | injunctions or the imposition   
 of civil or criminal penalties